profit from every $100 of sales.
$0$100
OrthoPediatrics
$32.35-0.71% today
+91.2% in 1 year
1-year low $14.641-year high $33.99
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What OrthoPediatrics sold, what it kept, and what it did with the cash.
Sales went from $122 million in 2022 to $236 million in 2025, with -$39.6 million of profit last year.
SalesProfit
OrthoPediatrics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OrthoPediatrics | No profit yet | ||
 Boston Scientific | 22.2× · Fair price | ||
 Koninklijke Philips | 30.1× · Expensive | ||
 Steris | 32.8× · Expensive | ||
 Zimmer Biomet Holdings | 27.7× · Fair price |
AI analysis
An AI analyst reads OrthoPediatrics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 122 | 149 | 205 | 236 | |
| 91 | 111 | 149 | 173 | |
| -22 | -26 | -30 | -29 | |
| -9 | -8 | -10 | -8 | |
| 1 | -21 | -38 | -40 | |
| 0.06 | -0.92 | -1.64 | -1.69 | |
| 74.1% | 74.8% | 72.6% | 73.1% | |
| -17.8% | -17.3% | -14.4% | -12.3% | |
| 1.0% | -14.1% | -18.5% | -16.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 428 | 439 | 473 | 509 |
| Cash | 9 | 31 | 44 | 20 |
| Total debt | 1 | 10 | 73 | 100 |
| Total liabilities | 49 | 62 | 119 | 162 |
| 379 | 377 | 355 | 347 | |
| 21 | 23 | 23 | 23 | |
| -4.5% | -5.3% | -5.5% | -5.1% | |
| 0.3% | -5.6% | -10.7% | -11.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -22 | -27 | -27 | -5 | |
| 10 | 17 | 14 | 11 | |
| -32 | -44 | -41 | -16 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 7 | 11 | 14 | 18 |
Valuation
- –
- –
- –
- 1.2×
- 3.6×
- –
- –
- -1.9%
- -4.7%
- 0.0%
Profitability
- 73.1%
- -12.3%
- -16.8%
- -4.9%
- -6.4%
- -5.8%
- -11.4%
- -7.9%
- -6.5%
- 3.7%
Growth
- +24.6%
- –
- +61.4%
- –
- +5.0%
Financial health
- –
- 0.31
- 21.2%
- -5.8×
- 5.21
- 2.37
- 0.48
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 26%of 952
Bottom 14%of 884
Top 22%of 887
Bottom 30%of 987
What analysts expect
- Average price target
- $21.00
- Range
- $17.00 – $25.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.42 | -0.38 | −10.5% |
| Feb 26, 2026 | -0.26 | -0.37 | +29.7% |
| Oct 28, 2025 | -0.24 | -0.26 | +7.7% |
| Aug 5, 2025 | -0.11 | -0.17 | +35.3% |
| May 7, 2025 | -0.39 | -0.26 | −50.0% |
| Mar 4, 2025 | -0.29 | -0.33 | +12.1% |
| Nov 6, 2024 | -0.18 | -0.12 | −50.0% |
| Aug 5, 2024 | -0.23 | -0.31 | +25.8% |
News
‘He was heartbroken’: My husband’s kids abandoned him when he was dying. Was he right to leave everything to me?MarketWatch · Nov 5, 2026My wife and I have no kids and a 99% chance of outliving our life savings. Why not spend it all?MarketWatch · Nov 3, 2026Want to help your adult kids and grandkids? Give them money while you’re still alive.MarketWatch · Nov 3, 2026My abusive ex-husband promised $20,000 for our kids’ education. Now he refuses to pay. Is he legally obligated?MarketWatch · Oct 31, 2026My husband wants to sell our $1.5 million home and downsize. But this is where we raised our kids — and I can’t bear to leave.MarketWatch · Oct 28, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
27No pass
Benjamin Graham
61Pass
Philip Fisher
40No pass
Peter Lynch
68Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
31No pass
Questions about OrthoPediatrics
Is OrthoPediatrics a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OrthoPediatrics AI analysis
What does OrthoPediatrics do?
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. It is in Medical - Devices.
Does OrthoPediatrics pay a dividend?
No. OrthoPediatrics does not pay a dividend at the moment.
Is OrthoPediatrics stock halal?
Yes. OrthoPediatrics passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
How has OrthoPediatrics stock done over the past year?
Up 91.2% over the past twelve months, to $32.35. It traded between $14.64 and $33.99 and is 4.8% below its high.
Who are OrthoPediatrics's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with OrthoPediatrics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.